COMP <GO>
DBD vs NATL // ALTMAN Z-SCORE & DEBT/EQUITY
Diebold Nixdorf Incorporated (NYSE) VS. NCR Atleos Corporation (NYSE) • 15-METRIC TALLY: DBD 4
— NATL 7
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: DBD
LAST: $59.14 (+1.84%) • MKT CAP: $1.99B
balance-sheet
1.79
LAST: $45.71 (+0.93%) • MKT CAP: $3.38B
balance-sheet
1.49
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DBD VS. NATL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DBD | NATL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 25.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.50% | 14.40% | -2.90 | NATL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.6x | 9.7x | +0.90 | NATL | /valuation <GO> |
| Free Cash Flow Yield | 15.14% | 7.08% | +8.06 | DBD | /fcf-yield <GO> |
| Operating Margin | 6.40% | 11.00% | -4.60 | NATL | /operating-margins <GO> |
| Net Profit Margin | 2.50% | 3.70% | -1.20 | NATL | /net-margins <GO> |
| Revenue Growth (YoY) | 1.50% | 1.10% | +0.40 | DBD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 1.79 | 1.49 | +0.30 | DBD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | DBD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.7 | 47.1 | -19.46 | NATL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.5x | 19.4x | +0.10 | NATL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.99B | $3.38B | -$1.39B | NATL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DBD REV | NATL REV | DBD GROSS % | NATL GROSS % | DBD FCF | NATL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.81B | $4.35B | 25.3% | — | $300.7M | $239.0M |
| FY 2024 | $3.75B | $4.30B | 24.5% | — | $149.2M | $257.0M |
| FY 2023 | — | $4.19B | — | — | — | $355.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DBD // BETA —
NATL // BETA —